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Abstract: Portal biliopathy refers to biliary tree abnormalities in patients with peribiliary collateral
vessels and non-neoplastic extrahepatic portal vein occlusion. These biliary abnormalities are
caused by vascular compression and ischemic damage of the biliary tree, which can result in bile
duct compression, stenosis, fibrotic strictures, bile duct dilation, and thickening of the bile duct
wall. Portal biliopathy is difficult to distinguish from cholangiocarcinoma, IgG4-related disease,
and sclerosing cholangitis. Although most patients are asymptomatic, portal biliopathy can lead to
serious complications, such as recurrent cholangitis. This case illustrates the importance of including
portal biliopathy in the differential diagnosis at an early stage, especially in patients with portal
hypertension. With early recognition, the need for additional invasive diagnostic procedures such
as biopsies is minimized. Pathogenesis, clinical presentation, diagnostics, and treatment options of
portal biliopathy are described in the article.
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1. Introduction
Portal biliopathy is caused by direct vascular compression and ischemic damage to the biliary tree
in patients with cavernous transformation of the portal vein caused by non-cirrhotic/non-neoplastic
chronic extrahepatic portal vein occlusion [1]. Although most patients with biliary dilation due to
portal biliopathy remain asymptomatic, jaundice, choledocholithiasis, and recurrent cholangitis do
occur [2]. Portal biliopathy mimics several other entities, such as cholangiocarcinoma or (auto-immune
and sclerosing) cholangitis. Therefore, it is important to be aware of the clinical presentation and
imaging characteristics of portal biliopathy to prevent unnecessary biopsy or surgery.
Our case illustrates that magnetic resonance imaging (MRI) combined with MR
cholangiopancreaticography (MRCP) and complementary endoscopic ultrasound (EUS) facilitate the
recognition of portal biliopathy. A timely diagnosis, however, remains challenging because portal biliopathy
can be a ‘great mimicker’ of cholangiocarcinoma, sclerosing cholangitis, and IgG4 cholangiopathy.
2. Case Report
A 52-year-old Afro-Caribbean man with a history of hypertension presented at our tertiary referral
center with longstanding abdominal pain in the right upper quadrant and unintentional weight loss of
10 kg in 12 months. The pain started immediately after eating, and worsened when eating food with
high amounts of fat. The patient did not complain of having fatty stools or diarrhea. His physical
examination was unremarkable. Laboratory investigations revealed increased levels of alkaline
phosphatase (168 U/L; reference <115 U/L), gamma-glutamyl transferase (244 U/L; reference <55 U/L),
Diagnostics 2020, 10, 623; doi:10.3390/diagnostics10090623 www.mdpi.com/journal/diagnostics
Diagnostics 2020, 10, 623 2 of 7
and total bilirubin (27 µmol/L; reference <17 µmol/L). There was no history of alcohol use or cigarette
smoking, and the family history was negative for relevant diseases. At presentation, our patient had
been unemployed for several years. Our patient has provided written informed consent.
Abdominal ultrasound showed a large mass between the liver hilus and the pancreatic head
(Figure 1), an enlarged spleen, and extensive collateral vessel formation. Contrast-enhanced computed
tomography (CT) confirmed the presence of this mass with encasement of the hepatic arteries and
common bile duct, dilation of the intrahepatic bile ducts, and portal vein thrombosis (Figure 2A,B).
Due to the vascular encasement, the mass was deemed irresectable. An esophago-gastroduodenoscopy
showed large esophageal varices. Elastography (FibroScan) showed only moderate (F2) liver fibrosis.
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Figure 2. Computed tomography images of the mass in the upper abdomen (arrows) in the arterial (A)
and portal veno s phase (B).
To exclude a neuroendocrine tumor, Gallium-68 DOTATOC and 18F fluorodeoxyglucose positron
emission tomography (PET) scans were performed, which showed no pathologic uptake. Follow-up CT
after three months demonstrated stable disease. Tumor markers (alpha fetoprotein and carbohydrate
antigen 19-9) and IgG4 levels remained within normal limits. IgG4 quantitative polymerase chain
reaction (qPCR), however, showed a value of 13.9% (reference <5%), compatible with IgG4 disease of
the pancreas and biliary tract [3]. Prednisolone treatment (40 mg/d, 6 weeks) for IgG4 disease, however,
did not decrease the size of the mass at follow-up CT.
Subsequently, EUS combined with fine needle biopsy, and MRI of the upper abdomen were
performed. EUS showed a highly vascular mass with a benign aspect. EUS-guided fine needle biopsy
was so ewhat difficult due to hardness of the mass. The histopathologic findings were most consistent
with a lesion of vascular origin, such as hemangio a. MRI of the upper abdomen revealed a large
mass surrounding the common bile duct, central intrahepatic bile ducts, cystic duct, and gallbladder,
without diffusion restriction. After administration of intravenous contrast medium, no enhancement
of the mass was visible in the arterial phase (Figure 3A). However, many small vessels were visible
within the mass in the portal venous phase (Figure 3B), with diffuse homogeneous enhancement of
the mass in the delayed phase (Figure 3C). At the MRCP, narrowing of the common bile duct was
visible along its complete course, combined with dilation of the intrahepatic bile ducts (Figure 3D).
At T2-weighted imaging, the mass around the narrowed common bile duct was slightly hyperintense
when compared to the liver parenchyma (Figure 3E).
After combining the findings during biopsy, at histopathology, and at all imaging modalities,
the large mass in the upper abdomen can be explained by an extreme manifestation of mass-forming
portal biliopathy. Additional analysis revealed a JAK2V617F mutation. This mutation leads to the
development of myeloproliferative neoplasms, a common underlying cause of non-cirrhotic portal
vein thrombosis [4]. Histopathological analysis after bone marrow biopsy confirmed the presence of
polycythemia vera in our patient.
Currently, our patient is in good condition. However, he has experienced several episodes of
iron-deficiency anemia, without signs of active bleeding in an esophago-gastroduodenoscopy. The iron-
deficiency anemia is most probably caused by chronic blood loss in the digestive tract, and he is now
being treated with oral iron therapy.
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Figure 3. Magnetic resonance imaging of the mass in the upper abdomen (arrows). Shown are T1
weighted subtraction images of the mass in the upper abdomen with fat suppression fter administration
of intravenous contrast medium in the arterial (A), portal v nous (B), and delayed phase (C). At magnetic
resonance cholangiopancreaticography, n rrowing of the mmon bile duct is visible along its complete
course (arrows), combined with dilation of the intrahepatic bile ducts (arrowheads) (D). At T2-weighted
im ging (E, coronal view), the mass surrounding the narrowed common bile duct was slightly
hyperintense, when compared to the liver parenc yma (arrows).
3. Discussion
After combining all diagnostic information, the large mass was ultimately diagn sed as an unusual
manifestati n of portal bili p thy. Because of the JAK2V617F mutation, the patient was more pr ne
to develop portal vein thrombosis, which c used extensive collateral vessel formation surr unding
the common bile duct, resulting in portal biliopathy. The main learning point in th present case is
that clinicians should know that portal biliopathy can present with a large mass surrounding the bile
ducts, especiall in patients with a high risk of thromb tic events. If we had thought of this possibility
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in an earlier stage, it would have been unnecessary to perform extensive diagnostic exams (such as
PET scans, EUS, and biopsies). In particular, when carefully evaluating the MR images, it is clear that
there are numerous small collateral vessels in the thickened wall of the common bile duct, indicating
the presence of collateral vessels due to chronic portal vein thrombosis, leading to portal biliopathy.
Thus, our case underlines the importance of being aware of this diagnosis, especially in patients with
portal hypertension, not only to prevent unnecessary biopsies and surgery, but also to shorten the
period of diagnostic uncertainty for the patient.
Portal biliopathy is defined as the presence of biliary abnormalities in patients with non-
cirrhotic/non-neoplastic extrahepatic portal vein obstruction [1,2]. After a (chronic) extrahepatic portal
vein thrombosis, collaterals develop to bypass the obstruction, resulting in cavernous transformation
of the portal vein. These collaterals, which involve the paracholedochal and epicholedochal venous
plexuses and cholecystic veins, cause extrinsic compression of the intra- and extrahepatic bile ducts.
In addition, underlying inflammatory and ischemic changes can result in peribiliary fibrosis [5].
The ischemic changes seem to be related to deficient portal blood supply of the bile ducts caused by
portal vein thrombosis and cavernous transformation of the portal vein, and to thrombosis of small bile
duct venules, resulting in stricture formation and fibrosis [6]. As in our patient, excessive deposition
of connective tissue around the bile ducts due to ischemia can lead to an extreme mass surrounding
the bile ducts [7]. In a slightly higher number of patients, biliary strictures seem to be caused by
mechanical obstruction, however, both mechanical compression and ischemic damage can play a role
in the pathogenesis of portal biliopathy [1,8].
Several studies have shown that bile duct changes occur in 81–100% of patients with extrahepatic
portal vein obstruction, while only 5–30% of patients with portal biliopathy present with symptoms of
biliary obstruction [5]. Clinical presentation includes abdominal pain, jaundice, recurrent cholangitis,
and cholecystitis [1,9]. Secondary biliary cirrhosis can develop in the case of prolonged bile
duct obstruction [10].
Portal biliopathy can be difficult to distinguish from cholangiocarcinoma, IgG4-related disease,
and sclerosing cholangitis. As illustrated by the present case, MRI and MRCP are important for
diagnosis, differential diagnosis, and follow-up. At MRCP, biliary stenosis, angulations, dilations,
choledochal varices, and lithiasis can be observed [1]. The optimal radiological imaging consists of
MRCP combined with contrast-enhanced MRI, thereby not only showing bile duct changes, but also
offering simultaneous visualization of the portal vein and collaterals [11]. In this way, important
information is obtained regarding the biliary and vascular abnormalities, which can guide the decision
of the most optimal treatment strategy. In case of longstanding portal vein thrombosis, the portal vein
is often difficult to visualize at CT or MRI due to fibrosis combined with collateral vessel formation,
which was also seen in our patient. Besides MRI/MRCP, EUS can be performed which sometimes
offers a more detailed evaluation of the biliary stenosis or mass, and can visualize pericholedochal
venous collaterals [12]. Also, EUS can be combined with fine needle biopsy, such as was performed in
our case. Endoscopic retrograde cholangio-pancreatography (ERCP) has no diagnostic role anymore,
because of its invasive character with associated risk of complications. Currently, in portal biliopathy
patients ERCP is reserved for therapeutic procedures only. To narrow down the differential diagnosis,
tumor markers and IgG4 level should be determined, and CT and/or PET-CT scans might be indicated.
Asymptomatic patients do not require any treatment. Treatment of symptomatic patients with
portal biliopathy should be individualized, with the aim of diminishing portal hypertension, and to
treat biliary strictures. The majority of patients need multiple treatments during their life, but a
consensus on the timing and priority of treatments is still not available [1].
4. Conclusions
Portal biliopathy can present with a large mass in the upper abdomen, due to extensive peribiliary
mass-forming fibrosis caused by the development of collateral veins and inflammatory and ischemic
changes after chronic portal vein thrombosis. It is an important diagnosis to be aware of, as it can
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mimic cholangiocarcinoma and cholangitis, which have their own treatment strategies and thus
have to be excluded before making the diagnosis of portal biliopathy. By understanding the clinical
presentation and diagnostic characteristics, patients will receive the best treatment, minimizing the
need for risky biopsies and surgical treatments, and shortening the period of diagnostic uncertainty for
patients. As can be learned from our case, in patients presenting with clear signs of portal hypertension,
combined with a peribiliary mass with homogeneous delayed enhancement, mass-forming portal
biliopathy should be considered the most likely diagnosis.
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